Mega Genomics Limited disclosed that it repurchased 92,000 ordinary shares on 29 September 2026, spending HKD 0.66 million at prices ranging from HKD 6.96 to HKD 7.15 per share. The volume-weighted average consideration was approximately HKD 7.13 per share.

The buyback, conducted under the general mandate approved on 21 May 2026, represents 0.0414 % of the company’s 222.31 million issued shares (excluding treasury shares) outstanding before the transaction. All repurchased shares have been retained as treasury stock; none were cancelled.

Post-transaction, issued shares (excluding treasury shares) decreased to 222.22 million, while treasury shares increased to 2.08 million. Total issued share capital remains unchanged at 224.30 million shares. Cumulatively, Mega Genomics has repurchased 2.08 million shares since the current mandate took effect—equivalent to 0.93 % of the share count on the mandate date—and retains the authority to repurchase up to 22.43 million shares in total.

Under Hong Kong Stock Exchange rules, the company is subject to a 30-day moratorium on new share issues or treasury share disposals, expiring on 29 October 2026.